Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TissueGen Inc.

http://www.tissuegen.com

Latest From TissueGen Inc.

Can Stents Pull Off a Disappearing Act?

Just three years ago bioabsorbable stents seemed to be more of a "nice to have" than a "need to have." After all,drug-eluting stents (DES) were seen as the answer to restenosis and showed very minimal risks to patient safety. But the recent concerns over DES have start-ups and corporations pushing harder for bioabsorbable stents.

Medical Device Platform Technologies

TissueGen Inc.

TissueGen, a start-up spun out of the University of Texas, is developing a bioabsorbable stent that permits the delivery of hydrophilic, or water soluable, therapeutics. If successful the sent would open up the door for a whole new family of drugs to be delivered via a stent.

Medical Device Platform Technologies

Start-Up Previews (01/07)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile groups are "Treating Traumatic Brain Injury," with profiles of Banyan Biomarkers, NeuroPharma AB, and RemeGenix; and "Can Stents Pull Off a Disappearing Act?," with profiles of Amaranth Medical, Bioabsorbable Therapeutics, and TissueGen Plus these Start-Ups Across Health Care: Design Medical, Kythera Biopharmaceuticals and Plethora Solutions.

Biocoatings: Not Just the Icing on the Cake

The successful commercialization of drug-eluting stents (DES) has done much to pave the way for the biocoating industy. DES not only helped establish a new regulatory body to facilitate device-drug reviews, the FDA Office of Combination Products, they also proved that biocoated devices could take market share from uncoated products, command premium pricing and premium reimbursement.

Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
UsernamePublicRestriction

Register